【允英学术】再添新证|允英医疗携手上海肿瘤医院证实血小板 PD-L1表达能预测肺癌病人的免疫治疗效果
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">打开公众号,设置“星标”,</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">关注<span style="color: black;">咱们</span></span><span style="color: black;"><span style="color: black;">认识</span><span style="color: black;">更加多</span>肿瘤<span style="color: black;">新闻</span>!~</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">血小板<span style="color: black;">PD-L1 mRNA</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">据<span style="color: black;">报告</span>,在非小细胞肺癌(NSCLC)中,血小板上的PD-L1蛋白可能反映肿瘤的整体PD-L1表达<span style="color: black;">状况</span>,对肿瘤的免疫逃逸机制起到<span style="color: black;">重要</span><span style="color: black;">功效</span>,并有助于克服肿瘤组织中PD-L1表达的异质性问题。来自肿瘤教育血小板(TEP)的mRNA<span style="color: black;">已然</span>被用于癌症的诊断、突变检测以及治疗效果的监控。然而TEP<span style="color: black;">源自</span>的PD-L1 mRNA的<span style="color: black;">功效</span>及与免疫治疗的<span style="color: black;">关联</span>性尚未被充分<span style="color: black;">科研</span>。</p><span style="color: black;">近期</span>,允英医疗携手上海复旦大学<span style="color: black;">附庸</span>肿瘤医院,借助于允英自主<span style="color: black;">开发</span>的采血管<span style="color: black;">制品</span>和RNAplus<span style="color: black;">有效</span>RNA提取技术以及允英Alldetect qPCR检测平台,探讨了晚期NSCLC<span style="color: black;">病人</span>TEP<span style="color: black;">源自</span>的PD-L1的<span style="color: black;">功效</span>,<span style="color: black;">发掘</span>高PD-L1水平的<span style="color: black;">病人</span>在接受免疫治疗后有更好的部分反应和较长的<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期(PFS),<span style="color: black;">显示</span>TEP<span style="color: black;">源自</span>的PD-L1可能<span style="color: black;">做为</span>预测免疫治疗效果的生物标记物。<span style="color: black;">关联</span>成果以论文“PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer”<span style="color: black;">发布</span>于SCI杂志<strong style="color: blue;">Translational Lung Cancer Research</strong>(IF=4.0,DOI:10.21037/tlcr-24-29),通讯作者为上海复旦大学<span style="color: black;">附庸</span>肿瘤医院肿瘤内科王佳蕾<span style="color: black;">专家</span>和<span style="color: black;">常建华<span style="color: black;">专家</span></span>,允英医疗CEO张道允博士及<span style="color: black;">开发</span>总监巩子英博士担任<span style="color: black;">一起</span>作者。<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMALRYu4CeRmbnDEGKLCHnvhnF6euehN7rNh4sWC7ld8vERXSAlAuztUg/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><img src="https://mmbiz.qpic.cn/mmbiz_gif/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMAoazTXXBjhWhBuSCZUica04FmQr6mMyPF1wUkYe1S5VichbMMuam2W0eQ/640?wx_fmt=gif&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1" style="width: 50%; margin-bottom: 20px;">本<span style="color: black;">科研</span>共入组72位NSCLC<span style="color: black;">病人</span>,<span style="color: black;">她们</span>接受了免疫单药或免疫联合化疗。<span style="color: black;">按照</span>RECIST 1.1标准,其中21位<span style="color: black;">病人</span>实现了部分缓解(PR),客观反应率(ORR)达到29.2%。有7位患者(9.7%)的稳定病(SD)<span style="color: black;">连续</span>时间超过6个月。经过中位15.8个月的随访,有52个病情<span style="color: black;">发展</span>(PD)或死亡事件。从72位<span style="color: black;">病人</span>中收集血液样本,离心收集血小板,提取mRNA进行PD-L1表达的检测。其中41位<span style="color: black;">病人</span>(占56.9%)有配对的组织样本PD-L1表达结果。皮尔逊<span style="color: black;">关联</span>性检验<span style="color: black;">表示</span>,<strong style="color: blue;">从TEP中提取的PD-L1与肿瘤组织PD-L1表达间<span style="color: black;">没</span><span style="color: black;">明显</span><span style="color: black;">关联</span>性(r=-0.19,P=0.233),即使在组织PD-L1呈阳性(TPS≥1%)的<span style="color: black;">病人</span>中<span style="color: black;">亦</span>是如此(r=-0.066,P=0.8)(见图1)。</strong>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMAG3CqRaTn1BRTT0lcKx0edIgiafWgMicNPj2pc17Id5ibYJfaaYXOAmksw/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">图1 描述了组织PD-L1 TPS(X轴)与TEP<span style="color: black;">源自</span>的mRNA值(Y轴)之间的关系。</span></strong></p>在这项<span style="color: black;">科研</span>中,基于TEP<span style="color: black;">源自</span>的PD-L1表达水平,<span style="color: black;">咱们</span>将<span style="color: black;">病人</span>分为高PD-L1组(36人)和低PD-L1组(36人)。在高PD-L1组中,PR的<span style="color: black;">病人</span>数量为16人,远高于低PD-L1组的5人(比例为44.4%对13.9%,P<0.01)。<span style="color: black;">另外</span>,高PD-L1组中有19名<span style="color: black;">病人</span>对免疫治疗产生反应(PR或PFS超过6个月),而低组仅有5名<span style="color: black;">病人</span>(比例为52.8%对13.9%,P<0.01)。更深入地分析<span style="color: black;">发掘</span>,高PD-L1组的中位PFS为8.3个月,<span style="color: black;">明显</span>长于低PD-L1组的2.8个月(P<0.001)。在仅接受免疫治疗的<span style="color: black;">病人</span>中,<span style="color: black;">表示</span>了<span style="color: black;">一样</span>的结果(8.0月对2.8月,P=0.002)。总<span style="color: black;">存活</span>期(OS)分析<span style="color: black;">表示</span>,高PD-L1组的中位OS尚未达到,而低PD-L1组的中位OS为13.5月(P=0.0047)。<span style="color: black;">尤其</span>是在仅接受免疫治疗的<span style="color: black;">病人</span>群体中,这种差异更<span style="color: black;">明显</span>(P=0.0126)。<strong style="color: blue;">有意思的是,即使<span style="color: black;">针对</span>组织PD-L1表达阴性(TPS<1%)的<span style="color: black;">病人</span>,高PD-L1组<span style="color: black;">一样</span><span style="color: black;">表示</span>出中位PFS的<span style="color: black;">明显</span>延长(8.1月对1.8月,P=0.0074)。</strong>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMAZNGexKOhX4XP92hLicXichWjla0CK8n0JMwG9TeBa2ib12xBUSYCjWbWA/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">图2. TEP<span style="color: black;">源自</span>的PD-L1 mRNA高表达组和低表达组之间的<span style="color: black;">存活</span>率。</strong></p><span style="color: black;">科研</span>进一步分析了经免疫治疗后<span style="color: black;">显现</span>不同临床反应NSCLC<span style="color: black;">病人</span>中TEP<span style="color: black;">源自</span>的PD-L1 mRNA表达差异(见图3)。<strong style="color: blue;">结果<span style="color: black;">发掘</span>,<span style="color: black;">得到</span>临床益处的<span style="color: black;">病人</span>(PR或PFS>6个月)的TEP<span style="color: black;">源自</span>PD-L1 mRNA表达量高于其他<span style="color: black;">病人</span>(中位数:2.97 vs. 3.44,P=0.012)。</strong>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMAXBeMHiaQ1E9XKss9IWNJ7oYxK3UmRLKKCR9KWrzFuI2swGPy15Iv0nA/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">图 3 不同临床反应NSCLC<span style="color: black;">病人</span>中TEP<span style="color: black;">源自</span>的mRNA表达值(Y轴)</span></strong></p><strong style="color: blue;">综上,此项<span style="color: black;">科研</span>提出,在接受免疫治疗的非小细胞肺癌<span style="color: black;">病人</span>中,检测血液中血小板源性PD-L1的表达,<span style="color: black;">能够</span><span style="color: black;">做为</span>预测治疗效果和<span style="color: black;">存活</span>预后的新生物标志物。且<span style="color: black;">科研</span><span style="color: black;">发掘</span>,血小板源性PD-L1与肿瘤中PD-L1的表达<span style="color: black;">没</span>关,<span style="color: black;">表示</span>其<span style="color: black;">做为</span>独立预测指标的<span style="color: black;">潜能</span>。<span style="color: black;">将来</span><span style="color: black;">科研</span>需进一步探究其在免疫疗效监测,尤其是耐药监测中的应用,并<span style="color: black;">评定</span>其与肿瘤突变负荷(TMB)、外泌体中PD-L1等其他生物标志物的<span style="color: black;">相关</span>性。</strong><img src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMA54Lbp6o8Rkj3WLYnAyzsOp3CmS4r03slfSoe4UbZOCNJOnsKMIlubw/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">温 馨 提 示</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">因为</span><span style="color: black;">微X</span>修改了推送规则,<span style="color: black;">无</span>点“在看”,会慢慢收不到<span style="color: black;">咱们</span>的推送哦。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">请将“<strong style="color: blue;"><span style="color: black;">允英</span></strong>”加为<strong style="color: blue;"><span style="color: black;">星标</span></strong>,每次阅读完后别忘记点下“<strong style="color: blue;"><span style="color: black;">赞</span></strong>”和“<strong style="color: blue;"><span style="color: black;">在看</span></strong>”哦。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">关于</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">允英医疗</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">YUNYING</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">允英医疗以长三角区域为中心,辐射全中国,<span style="color: black;">机构</span>致力于打造癌症<span style="color: black;">精细</span>诊疗的新型生态圈,综合运用基因突变检测、基因甲基化检测、基因编辑重组等生物科技的前沿技术,全方位<span style="color: black;">供给</span>从癌症<span style="color: black;">初期</span><span style="color: black;">精细</span>筛查、癌症靶向用药检测、癌症治疗<span style="color: black;">药品</span><span style="color: black;">开发</span>一体化的肿瘤<span style="color: black;">精细</span>医学<span style="color: black;">处理</span><span style="color: black;">方法</span>。<span style="color: black;">日前</span>在上海、浙江及青海共设有三家实验室。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">允英医疗成立<span style="color: black;">迄今</span>,顺利<span style="color: black;">经过</span>由国家卫健委临检中心、国家病理质控中心、美国病理学会等<span style="color: black;">公司</span>组织的室间质评。检验能力<span style="color: black;">得到</span>了美国病理学会(College of American Pathologists,CAP)认证,肿瘤核心基因检测试剂盒<span style="color: black;">经过</span>欧盟CE认证,<span style="color: black;">得到</span>国家<span style="color: black;">药物</span>监督管理局(NMPA)注册<span style="color: black;">准许</span>,且生产管理质量体系获国际ISO13485认证。<span style="color: black;">日前</span>允英已累计为近三十万例肿瘤<span style="color: black;">病人</span><span style="color: black;">供给</span><span style="color: black;">精细</span>检测服务,为国内肿瘤<span style="color: black;">精细</span>医疗<span style="color: black;">行业</span>开拓者。<span style="color: black;">同期</span>允英秉承“严谨、<span style="color: black;">有效</span>”的理念,坚守分子诊断技术创新与应用探索,为肿瘤<span style="color: black;">精细</span>医疗与<span style="color: black;">伴同</span>诊断<span style="color: black;">行业</span>的茁壮发展贡献力量。</p><img src="https://mmbiz.qpic.cn/mmbiz_png/VDlEhgBX2kNVqcJX04Hxg3WYbx9XzkMABq34TMoIQgjJjBnmUJOCc8PhngK2RcBKFoC7iaXmiaBsuficWUQAaWsAg/640?wx_fmt=png&from=appmsg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
我赞同你的看法,你的智慧让人佩服,谢谢分享。 期待更新、坐等、迫不及待等。 你的话语如春风拂面,温暖了我的心房,真的很感谢。 楼主听话,多发外链好处多,快到碗里来!外链论坛 http://www.fok120.com/ 说得好啊!我在外链论坛打滚这么多年,所谓阅人无数,就算没有见过猪走路,也总明白猪肉是啥味道的。
页:
[1]